The Latest Breaking News from Obesity

As Congress pushes for Medicare to cover anti-obesity drugs, puzzlement remains about who should get them, for how long, and at what price.

Danish company, which also makes Ozempic, faces increasing competition from US rival Eli Lilly

It’s no secret old age can rob us of our strength. This age-related muscle wastage – known as sarcopenia – can eventually lead to more falls, more hospital stays, difficulty with walking or toileting and less independence. Eventually, it can mean needing residential aged care.

"We're in the Ozempic era," says plus-size supermodel Hunter McGrady, the new cover woman for 2024 Sports Illustrated Swimsuit. The post “We’re In The ‘Ozempic Era'”: Plus-Size Model Calls For Self-Acceptance After Joining SI Cover first appeared on Bored Panda.

Cancer rates in Millennials and Gen X have risen sharply along with obesity rates

Tirzepatide, a drug for diabetes and obesity, has sent the 148-year-old pharma giant on a wild ride. It’s now the ninth most valuable company in the world.

Evidence has grown that school BMI screenings aren’t helpful and can even be harmful. Why do they persist?

Research suggests large fat cells predict weight loss, while small fat cells may lead to weight gain over time.‌ New insights into how fat cell size influences weight dynamics in a study presented to the European Congress on Obesity. ‌

Most diseases can’t be treated solely with lifestyle intervention, and obesity is no exception.

“BMI doesn't tell you what I can do, what I do on the field, how much muscle I have,” Ilona Maher said. The post Olympic Athlete Has The Perfect Response About BMI After Viewers Mock Her Weight first appeared on Bored Panda.

Pfizer's stock shows signs of a potential rebound, buoyed by recent pipeline successes in hemophilia and obesity treatments, an attractive 5% dividend yield, and a rock-bottom valuation. This makes it an appealing dividend stock for value and income investors as the drug giant prepares to report earnings.